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Hypoxia and in ammation play a major role in the revascularization 
following ischemia. Sildena l inhibits phosphodiesterase-5, 
increases intracellular cGMP content and thus induces vasodilation. 
Sildena l also induces neovascularization following ischemia but 
through a pathway remaining incompletely understood. Thus, we 
investigated the consequences of a long-term sildena l treatment 
on post-ischemic revascularization.
The left femoral artery was ligated in sildena l (25 mg/kg per 
day)-treated rats. Vascular density and blood  ow were evaluated 
in both legs and expressed as left/right leg (L/R) ratio. After 7 
or 21 days, the L/R ratio was 33¡Ó2 % and 54¡Ó9 %, respectively 
in control rats. Sildena l increased signi cantly the ratio to 
47¡Ó4 % and 128¡Ó11 %, respectively. A neutralizing VEGF antibody 
signi cantly decreased vascular density (x0.48-fold) in control rats 
without affecting density in sildena l-treated animals. Blood  ow 
and arteriolar density followed the same pattern. In the ischemic 
leg, HIF1ƒÑ and VEGF expression level increased in control, not 
in sidena l ¡Vtreated rats, suggesting that sildena l might not 
preferentially induce angiogenesis. PI3-kinase, Akt and eNOS 
were activated after 7 days with a down-regulation after 21 days. 
Sildena l-induced migration of endothelial cells was prevented 
by PI3-kinase inhibition with LY294002. Finally, sildena l-induced 
rise in blood  ow in mesenteric resistance arteries was associated 
with an increased luminal diameter (outward remodeling or 
arteriogenesis). This arteriogenesis was also associated with eNOS 
proteins activation.
Conclusion — Long term sildena l treatment increased local blood 
 ow and collateral arteries growth independent of VEGF but in 
association with activation of PI3-kinase, Akt and eNOS which 
might preferentially activate arteriogenesis.
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CD4+ and CD8+ T lymphocytes control revascularization after 
vascular occlusion. T cell activation is mediated by two major 
costimulatory signalings: the B7/CD28 and the CD40-CD40 ligand 
pathways. Interestingly, CD28 interactions with the structurally 
related ligands B7-1 and B7-2 are also required for the generation 
and homeostasis of CD4+CD25+ regulatory T cells (Treg), which 
actively maintain immunological tolerance to self and nonself 
antigens. We hypothesized that naturally arising Treg modulate 
the immuno-in ammatory response to ischemic injury, and 
subsequently vessel growth.
Ischemia was induced by right femoral artery ligation in CD28-
de cient mice (n=10 per group). After 21 days of ischemia, 
CD28 de ciency showed a profound reduction in Treg number 
and upregulated post-ischemic in ammatory response and 
neovascularization. Similarly, injection of splenocytes isolated from 
CD28-/- mice in Rag1-/- mice with hindlimb ischemia increased 
angiographic score, foot perfusion, and capillary density by 2.2-, 
2.3- and 1.1-fold, respectively, compared to PBS-injected Rag1-/- 
mice. These effects were associated with enhanced accumulation 
of CD3-positive T cells and Mac-3 positive macrophages in the 
ischemic leg of Rag1-/- mice treated with CD28-/- splenocytes. 
Interestingly, cotransfer of Treg with CD28-/- splenocytes in Rag1-
/- mice abrogated activation of neovascularization induced by 
CD28-/- splenocytes. In ammatory cells accumulation was also 
decreased in Rag1-/- transplanted with both Treg and CD28-/- 
splenocytes compared to mice receiving CD28-/- splenocytes only. 
In contrast, treatment of C57Bl/6 Wild-Type mice with an anti-
CD25 antibody (PC61) markedly reduced endogenous Treg levels 
in blood and spleen. At day 14 of ischemia, in ammatory response 
and neovascularization were markedly increased in anti-CD25 
treated Wild-Type mice compared to untreated mice. These results 
provide new insights into the immunoregulation of post-ischemic 
neovascularization.
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Diabetes-induced reactive oxygen species overproduction impairs 
neovascularization. CHOP 10 is a novel developmentally regulated 
nuclear protein that emerges as critical transcriptional integrator 
among pathways regulating differentiation, proliferation and 
survival. Of interest, CHOP-10 has been shown to trigger oxidative 
stress-induced β cells apoptosis in the setting of diabetes. Here, 
we analyzed the role of CHOP-10 in postnatal neovascularization 
and bone-marrow-derived mononuclear cells (BMC) pro-angiogenic 
potential in type I diabetic mice with hindlimb ischemia.
Ischemia was induced by right femoral artery ligation in C57/
Bl6 animals (WT, n=8), diabetic C57/Bl6 animals (diab WT, n=8, 
Streptozotocin 40 mg/kg) and diabetic CHOP-10—de cient animals 
(diab CHOP-10 KO, n=8). Two days after ischemia, CHOP-10 mRNA 
and protein levels were increased by 7- (p<0.001) and 4-fold 
(p<0.01), respectively in ischemic muscle of WT diab compared to 
WT. Angiographic score, capillary density and foot perfusion were 
increased by 3.3- (p<0.01), 1.8- (p<0.001) and 2.2-fold (p<0.001) 
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in diab CHOP-10 KO compared to WT diab, 21 days after ischemia. 
This effect was associated with a reduction in the number of 
apoptotic cells and an increase in eNOS levels in diab CHOP-
10 KO compared to WT diab. We next analyzed the role of CHOP-
10 in post-natal vasculogenesis. Injection of BMC isolated from 
diab CHOP-10 KO in WT mice with hindlimb ischemia improved 
neovascularization by around 1.8-fold when compared to WT diab 
BMC (p<0.05). BMC isolated from diab CHOP-10 KO mice showed 
an upregulation of eNOS protein levels and an increase in their 
ability to differentiate into cells with endothelial phenotype in 
vitro differentiation assay. Finally, treatment of cultured HUVEC 
with homocysteine increased CHOP-10 mRNA levels and repressed 
eNOS gene expression. Consistent with these results, eNOS protein 
expression was signi cantly upregulated in the CHOP-10 siRNA—
transfected endothelial cells. Additionally, overexpression of 
CHOP-10 inhibited the basal transcriptional activation of the eNOS 
promoter as assessed by a reporter gene assay using a 3,500-bp 
fragment of the human eNOS gene.
Our study unravels an important inhibitory role of CHOP-10 in the 
regulation of vessel formation in the setting of diabetes.
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Hypoxia stimulates angiogenesis during development, as well as in 
the course of ischemic cardiovascular diseases and tumor growth. 
In a hypoxic environment, endothelial cells (EC) are key players 
of the angiogenic response. Their activation leads to remodeling 
of the extracellular matrix (ECM): a degradation step generates 
a provisional ECM supporting EC proliferation and migration ; 
assembly of a new basal lamina leads to pericyte recruitment and 
neovessel maturation.
In order to identify endothelial ECM proteins regulated by hypoxia, 
2D gel electrophoresis was performed on ECM samples prepared from 
cultured EC of micro or large vessels (HDMEC or HUVEC respectively). 
Mass spectrometry identi ed lysyl oxidase-like protein 2 (LOXL2) as a 
highly hypoxia-induced protein. Lysyl oxidases are secreted enzymes 
involved in ECM maturation through covalent cross-linking of its major 
components, collagens and elastin. The induction of LOXL2 expression 
was detected both at the mRNA and protein levels. Using siRNA, we 
demonstrated that LOXL2 is responsible for 65 % of lysyl oxidase total 
activity in hypoxic EC. In addition, LOXL2 protein was colocalised with 
type IV collagen in endothelial ECM.
We further investigated the expression of LOXL2 in vivo. The 
enzyme was expressed in rat EC from retina during postnatal 
vascular development, and from adult skeletal muscle. In a murine 
model of hindlimb ischemia, LOXL2 was upregulated at the protein 
and mRNA levels. In situ hybridization revealed its expression in 
both EC and macrophages.
Involvement of LOXL2 at different steps of the angiogenic process 
was further studied in vitro. We demonstrated that LOXL2 increases 
EC migration on  bronectin, as well as migration and tube formation 
in  brin 3D gels. In addition, LOXL2 knock-down inhibited type IV 
collagen deposition in the ECM, suggesting a major role for LOXL2 
in the organisation of endothelial basal lamina. Finally, whereas the 
ef ciency of endothelial ECM for recruiting VSMC was increased by 
hypoxia, this effect was reduced upon knocking down endothelial 
LOXL2 expression. Altogether, these data suggest that LOXL2 plays a 
major role in EC migration, vascular basal lamina deposition and neo-
vessel stabilisation during hypoxia-induced angiogenesis.
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Cell-based therapy is a promising option for treatment of 
cardiovascular diseases. Based on experimental studies 
demonstrating that bone marrow-derived mononuclear cells 
(BMMNCs) improve the functional recovery after ischemia, clinical 
trials were initiated to address this new therapeutic concept. 
BMMNCs improve neovascularization of ischemic tissue by a 
broad repertoire of potential therapeutic actions. Whereas initial 
studies documented that the cells incorporate and differentiate 
to cardiovascular cells, other studies suggested that short-time 
paracrine mechanisms mediate the bene cial effects. Here, we 
hypothesized that BMMNCs have a phagocytic ability, and switch 
to a proangiogenic phenotype after engulfment of apoptotic 
cells. Activation of such angiogenic program may be pivotal in 
the bene cial effect of BMMNCs-based therapy. In vitro, wild-
type (WT) BMMNCs ingestion of apoptotic cells upregulated the 
release of proangiogenic factors VEGF and HGF by 15- and 5-fold, 
respectively. In contrast, BMMNCs collected from mice de cient in 
MFG-E8, a protein that is required for attachment and engulfment 
of apoptotic cells by phagocytes, displayed lower phagocytic 
ability, leading to decrease in VEGF and HGF release. The capacity 
of BMMNCs to differentiate into cells with endothelial phenotype 
was similar in control and MFG-E8-de cient cells. In an in vivo 
model of mice myocardial infaction (MI), transplantation of WT 
BMMNCs increased fractionnal shortening (120 % of untreated 
control, p<0.05), 14 days after MI. Size of the infarct scar was 
reduced by 30 % (p<0.05 vs untreated control), and capillary density 
in the infarct border zone was raised by 10 % (p<0.05 vs untreated 
control) in the WT BMMNCs group. In contrast, transplantation 
of MFG-E8 de cient BMMNCs displayed no signi cant effect on 
cardiac function, infarct size or angiogenesis in the ischemic 
myocardium. Four days after MI, VEGF protein levels were raised 
by 1.4 fold in the myocardium of WT BMMNCs treated animals 
compared to untreated controls (p<0.05), while treatment with 
MFG-E8 de cient BMMNCs failed to raise VEGF levels. Taken 
together, these results suggest that phagocytosis of apoptotic 
cells reprograms BMMNCs into a proangiogenic phenotype. Hence, 
the therapeutic effect of transplanted BMMNCs depends, at least 
in part, on their phagocytic ability.
